Stories
Virupaksha Organics Completes Rs 104-Crore Acquisition of Vivin Drugs Ahead of IPO
M
Moneycontrol•06-10-2026, 18:44
Virupaksha Organics Completes Rs 104-Crore Acquisition of Vivin Drugs Ahead of IPO
- •IPO-bound Virupaksha Organics has successfully completed the Rs 104-crore acquisition of insolvent drugmaker Vivin Drugs & Pharmaceuticals and Vivin Laboratories.
- •The acquisition was finalized following approval from the NCLT Hyderabad bench on August 21, with 98.2 percent of lenders voting in favor.
- •The deal brings valuable anti-retroviral active pharmaceutical ingredients into Virupaksha's portfolio, enhancing its manufacturing platform.
- •Virupaksha operates six manufacturing facilities across Telangana and Karnataka, offering a portfolio of 54 products to customers in over 100 countries.
- •The company is preparing for a Rs 740-crore public issue, intending to use a portion of the proceeds for capacity expansion and debt repayment.
Key Questions Answered
Virupaksha Organics completed the acquisition of Vivin Drugs & Pharmaceuticals and Vivin Laboratories by implementing a Rs 104-crore resolution plan approved by the NCLT.
The acquisition is aimed at strengthening Virupaksha's manufacturing footprint, widening its product basket, and enhancing its active pharmaceutical ingredient (API) portfolio—particularly in anti-retroviral APIs—ahead of its proposed IPO.
Virupaksha has filed draft papers with Sebi for a Rs 740-crore public issue, planning to deploy Rs 360 crore towards capacity expansion and Rs 195 crore toward debt repayment.
